Payment overview · 2025
General Payments
$130.93
7 reported records · 5 companies
Healthcare provider profile · identity verified
Rogers Pressley Fair, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DALLAS, TX · NPI 1063476463
Verified facts
What the public records show
CMS Open Payments records show Rogers Pressley Fair, MD received $130.93 in general payments during 2025 across 7 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.61 | 44.8% | 3 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $22.93 | 17.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.21 | 13.1% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $16.72 | 12.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.46 | 11.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.93 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $25.81 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 433 | 135 |
| Losartan Potassium | Losartan Potassium | 317 | 94 |
| Hydrochlorothiazide | Hydrochlorothiazide | 289 | 89 |
| Nifedipine Er | Nifedipine | 241 | 62 |
| Furosemide | Furosemide | 225 | 71 |
| Lisinopril | Lisinopril | 151 | 44 |
| Potassium Chloride | Potassium Chloride | 150 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 39 |
| Tramadol Hcl | Tramadol Hcl | 127 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 123 | 46 |
| Metformin Hcl | Metformin Hcl | 117 | 35 |
| Gabapentin | Gabapentin | 105 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 30 |
| Omeprazole | Omeprazole | 96 | 33 |
| Montelukast Sodium | Montelukast Sodium | 84 | 24 |
| Carvedilol | Carvedilol | 79 | 24 |
| Clonidine Hcl | Clonidine Hcl | 78 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 30 |
| Donepezil Hcl | Donepezil Hcl | 71 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 25 |
| Trazodone Hcl | Trazodone Hcl | 67 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 16 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Allopurinol | Allopurinol | 45 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 15 |
| Buspirone Hcl | Buspirone Hcl | 42 | 17 |
| Eliquis | Apixaban | 42 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 12 |
| Simvastatin | Simvastatin | 37 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 14 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Glipizide | Glipizide | 34 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Memantine Hcl | Memantine Hcl | 32 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Alprazolam | Alprazolam | 21 | 11 |
| Torsemide | Torsemide | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 16 |
| Atenolol | Atenolol | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Cephalexin | Cephalexin | 14 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Topiramate | Topiramate | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.93 · 7 records | Boehringer Ingelheim Pharmaceuticals, Inc. | CT THROMBECTOMY SYSTEM KIT, FLOWTRIEVER CATHETER, S, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, Veozah, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error